The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -32,250 | -71,691 |
| Depreciation and amortization | 3,227 | 6,611 |
| Stock-based compensation | 4,861 | 14,535 |
| Accretion and amortization of premiums and discounts on investments, net | 810 | 1,915 |
| Deferred revenue | 4 | -393 |
| Change in fair value of stock price appreciation milestones | 90 | -207 |
| (gain) loss on disposal of property and equipment | 0 | 36 |
| Accounts receivable | -713 | -2,144 |
| Prepaid expenses and other assets | -1,026 | -3,139 |
| Accounts payable and accrued expenses | -550 | -9,342 |
| Right-of-use assets and lease liabilities, net | -685 | -1,241 |
| Net cash used in operating activities | -24,374 | -58,396 |
| Proceeds from sale of property and equipment | 3 | 122 |
| Purchases of property and equipment | 2,203 | 2,558 |
| Purchases of investments | 57,975 | 99,437 |
| Maturities of investments | 81,447 | 164,137 |
| Net cash provided by (used in) investing activities | 21,272 | 62,264 |
| Issuance of common stock from equity incentive plans, net of issuance costs | 0 | 0 |
| Proceeds from public offering of common stock, net of issuance costs | 0 | 0 |
| Proceeds from issuance of pre-funded warrants, net of issuance costs | 0 | 0 |
| Proceeds from ft819 cirm award | 0 | 0 |
| Proceeds from ft836 cirm award | -2,475 | -1,325 |
| Net cash provided by financing activities | 2,475 | 1,325 |
| Net change in cash, cash equivalents and restricted cash | -627 | 5,193 |
| Cash and cash equivalents at beginning of period | 46,283 | - |
| Cash and cash equivalents at end of period | 50,849 | - |
FATE THERAPEUTICS INC (FATE)
FATE THERAPEUTICS INC (FATE)